Andrea Woltman

Andrea WoltmanAssociate Professor
Room: NA-1006

Research areas: Immunology of viral hepatitis and virus-associated hepatocellular carcinoma

Andrea Woltman studied Biomedical Sciences at the University of Leiden, The Netherlands (1993-1998; cum laude). She performed her PhD-study at the Department of Nephrology of the Leiden University Medical Center in Leiden and the Laboratory for Immunological Research of Schering-Plough in Dardilly, France. She defended her thesis about functional modulation of human dendritic cells in kidney transplantation cum laude in 2002. She continued her research on regulation of human dendritic cell function and development at the Department of Nephrology in Leiden and focussed on dendritic cells as potential tools and targets to prevent allograft rejection. In 2006, she became group leader and staff member at the Department of Gastroenterology and Hepatology of the Erasmus MC in Rotterdam. Since 2013 she is appointed as associate professor. She is leading a research group on the immunology of viral hepatitis, especially chronic hepatitis B, and virus-associated hepatocellular carcinoma. Her research group aims (1) to determine the immunological factors and processes involved in viral clearance and persistence and development of virus-associated hepatocellular carcinoma, and (2) to develop effective immunotherapies to cure chronic viral hepatitis and hepatocellular carcinoma. Main immunological and molecular processes that are studied include viral antigen presentation, virus-host interaction and regulation of antigen-specific T cell responses, in which dendritic cells play a major role.
She published many research papers and several book chapters, received many research grants, including the prestigious VENI and VIDI grants from ZonMW/NWO, and received several awards during her scientific career. As member of the Editorial Board of Immuun, the journal of the Dutch Society for Immunology, she contributed to a better access and knowledge about immunology for a broad audience. Furthermore, since 2013 she is a selected member of Young Erasmus, a network of talented scientists of the Erasmus University Rotterdam that advises the Executive Board of the university on research policy and aims to strengthen interdisciplinary research, which she chaired from 2013-2015. As the Director of education of the Bachelor Medicine (since 2013), she is also strongly involved in education within the Erasmus MC.

 The researchgroup

Selected Publications

Hepatitis B surface antigen activates myeloid dendritic cells via a soluble CD14-dependent mechanism.
Van Montfoort, Van der Aa E, Van den Bosch A, Brouwers H, Vanwolleghem T, Janssen HLA, Javanbakht H, Buschow S, Woltman AM
J Virol., in press.

To target or not to target viral antigens in HBV related HCC?
Buschow SI, Sprengers D, Woltman AM.
J Hepatol. 2015 Jun;62(6):1449-50.

Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function.
Boltjes A, van Montfoort N, Biesta PJ, Op den Brouw ML, Kwekkeboom J, van der Laan LJ, Janssen HL, Boonstra A, Woltman AM.
J Infect Dis. 2015 Apr 15;211(8):1268-78

The role of Kupffer cells in hepatitis B and hepatitis C virus infections.
Boltjes A, Movita D, Boonstra A, Woltman AM.
J Hepatol. 2014 Sep;61(3):660-71

Understanding MHC class I presentation of viral antigens by human dendritic cells as a basis for rational design of therapeutic vaccines.
van Montfoort N, van der Aa E, Woltman AM.
Front Immunol. 2014 Apr 23;5:182

PI3K-PKB hyperactivation augments human plasmacytoid dendritic cell development and function.
van de Laar L, van den Bosch A, Boonstra A, Binda RS, Buitenhuis M, Janssen HL, Coffer PJ, Woltman AM.
Blood, 120(25):4982-4991, 2012.

Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy.
van de Laar L, Coffer PJ, Woltman AM.
Blood, 119(15):3383-3393, 2012.

Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B virus infection.
Tjwa ET, van Oord GW, Biesta PJ, Boonstra A, Janssen HL, Woltman AM.
J. Virol., 86(8):4102-4109, 2012.

Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.
Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM.
J. Hepatol. 54(2): 209-18, 2011.

Dendritic cells in chronic viral hepatitis B and C: victims or guardian angels?
Woltman AM, Boonstra A, Janssen HL.
Gut 59(1):115-25, 2010.

Pubmed search for A. Woltman